




Clearsight Advisors[®]
Investment Banking



Q2 2026

Healthcare and Life Sciences Services Market Monitor

Market Update, Industry News, Sector Spotlight, and M&A Activity



Select Industry News

Ampersand Capital Partners Closes Latest Fund at \$1.5B

Ampersand 2026 ("AMP-26"), which closed at its hard cap in less than five months, represents the firm's twelfth primary fund since 1992. Commitments to the oversubscribed fund came from a broad range of institutional investors worldwide, including endowments, pension plans, and insurance companies, highlighting sustained global demand for specialized healthcare and life sciences investment opportunities. ([Link](#))¹

AWS Launches Amazon Bio Discovery to Accelerate AI-Powered Life Sciences Research

The application gives scientists direct access to specialized AI models that are trained on large biological datasets. By combining this access with the application's AI agent, AWS aims to enable scientists to build and test molecules with meaningfully increased speed and precision. ([Link](#))²

GHO Capital and CBC Group to Merge and Form World's Largest Healthcare Investment Firm

The combined firm will manage \$21 billion in assets and leverage the expertise of more than 200 investment and operating professionals across 13 global offices. This expanded platform will enhance its ability to serve investors while continuing to support founders and portfolio companies across pharmaceuticals, medical devices, life sciences tools, and healthcare IT. ([Link](#))³

Leading Life Sciences Consultancies Launch as Acumetis, a Single Integrated Brand

Acumetis was formed through the combination of Herspiegel, Adivo Associates, Decisive Consulting, Fiecon, and Sixsense Strategy Group. By bringing commercial strategy, launch excellence, patient support, insights, and medical affairs under one roof, the platform is well-positioned to support the full demands of life sciences organizations across the entire product lifecycle. ([Link](#))⁴

OpenAI Launches GPT-Rosalind for Life Sciences Research

OpenAI is working to implement GPT-Rosalind with enterprise life sciences companies including Amgen, Moderna, and Thermo Fisher Scientific to accelerate workflows by supporting evidence synthesis, hypothesis generation, and other multistep research tasks in the early stages of discovery. ([Link](#))⁵

Sidnee Pinho Joins Opus Regulatory as CEO

Drawing on decades of leadership experience in the life sciences industry, Pinho will further advance Opus's mission of supporting clients through the increasingly complex regulatory, clinical, and medical requirements associated with developing and commercializing innovative medicines. ([Link](#))⁶

Tegria Appoints Craig Mengert as CEO

Mengert succeeds Brian Cahill, bringing extensive experience driving growth in healthcare organizations. The appointment builds on the momentum of Tegria's acquisition by Altaris in 2026, bolstering the firm's ability to support providers and payers as they seek to modernize their technology infrastructures and reduce operating costs. ([Link](#))⁷

Sector Leadership



Greg Treger
Managing Director
[Email Greg](#)



Tory Steel
Managing Director
[Email Tory](#)



Austin Kuhn
Director
[Email Austin](#)



Jonathan Holland
Vice President
[Email Jonathan](#)

Target**Blue Matter***(Baird Capital)*Acquirer**Ares & Baird Capital****Deal Commentary**

- Blue Matter is a strategic consultancy that helps biopharmaceutical companies maximize product and portfolio value through commercialization, market access, and analytics solutions
- Ares & Baird Capital's investment reflects continued confidence in Blue Matter's differentiated positioning and enables accelerated growth across communications, market access, and patient services

Transaction Summary

On May 5, 2026, Baird Capital announced the closing of a continuation fund led by Ares to support Blue Matter. The transaction provides additional capital and strategic flexibility to accelerate growth across Blue Matter's medical communications, market access, patient services, and analytics capabilities

Transaction Information

Announced Date	May 5, 2026
Deal Type	Continuation Vehicle
<i>Target Information</i>	
Year Founded	2012
Target HQ	San Francisco, CA
# of Employees	~400

Target**Helio Health Group**Acquirer**WestView Capital Partners****Deal Commentary**

- Helio is an AI and tech-enabled services firm helping pharma, biotech, and healthcare clients address compliance, government pricing, commercial contracting, and operational challenges
- WestView Capital's investment expands Helio's ability to further develop AI-driven solutions, enhancing offerings across commercialization, pricing, and regulatory capabilities

Transaction Summary

On June 3, 2026, Helio Health announced a strategic minority investment from WestView Capital Partners. Proceeds are expected to drive Helio's AI-focused solution development, ultimately enabling clients to navigate increasingly complex commercial and regulatory environments

Transaction Information

Announced Date	June 3, 2026
Deal Type	Minority Investment
<i>Target Information</i>	
Year Founded	2015
Target HQ	Morristown, NJ
# of Employees	~50

Healthcare and Life Sciences Services Deal Volume¹

■ Merger / Acquisition ■ Buyout / Growth Investment ■ Add-on



1. Time series data based on Clearsight's custom PitchBook screen intended to show trends over time and should be interpreted as directional regarding deal volume. Please email the Clearsight team for specific screen-related questions.



Date	Target	Buyer	Summary
6/30/2026	Deerfield Agency (Edgewater)	Martis Capital	Deerfield is an integrated marketing, media, communications, and technology agency that supports healthcare and pharma clients
6/22/2026	KMK Consulting	Tredence (Advent)	KMK is a Veeva Partner and consultancy serving pharmaceutical companies across RWE, HEOR, commercial operations, and analytics
6/17/2026	Ensemble Health Partners (Berkshire, Warburg Pincus, Golden Gate)	Thoreau Group (Apollo)	Ensemble is a provider of revenue cycle management services intended to help healthcare organizations optimize financial performance and reduce administrative friction in healthcare operations
6/11/2026	Empierus	Vizient	Empierus is a provider of IT contracting, technology management, and cost optimization services, helping healthcare providers improve financial performance and operational efficiency
6/3/2026	RelateCare (MML Capital)	Huron Consulting	RelateCare is a provider of AI-enabled clinical and patient access solutions and revenue cycle management services for healthcare organizations
6/3/2026	Helio Health Group	WestView Capital Partners	Helio is an AI and technology-enabled services firm that helps pharma, biotech, and healthcare clients address complex compliance, government pricing, commercial contracting, and operational challenges
6/2/2026	AppliedPX	Reservoir Communications Group (Periscope)	AppliedPX is a provider of patient-centered healthcare research and advisory services intended to support patient organizations, pharmaceutical companies, trade associations, and healthcare stakeholders
5/24/2026	Yonalink	Veeva Systems	Yonalink is a healthcare technology company that provides software solutions for integrating and managing clinical research data, enabling the automated transfer of patient data from healthcare systems into clinical trial workflows

Source: Pitchbook, company websites, Business Wire, Public filings.



Date	Target	Buyer	Summary
5/11/2026	PayerAlly	HealthScape Advisors (Chartis)	PayerAlly is a pharmacy consulting firm specializing in pharmacy benefit management (PBM) strategy, procurement, and optimization
5/6/2026	Cross Country Healthcare	Knox Lane	Cross Country is a technology-driven healthcare workforce solutions company, delivering staffing and advisory services to help health systems optimize and sustain their labor ecosystems
5/5/2026	Blue Matter¹ (Baird Capital)	Ares & Baird Capital	Blue Matter is a strategic consultancy that helps biopharmaceutical companies maximize product and portfolio value through commercialization, market access, and analytics solutions
5/5/2026 ²	CAI	JLL Partners	CAI is a global consulting firm providing commissioning, qualification, and validation management services to a global client base of pharmaceutical manufacturers, driving operational readiness and excellence
5/4/2026	Canopii Collaborative	Impact Advisors (Chicago Pacific)	Canopii is a healthcare consulting firm specializing in Epic payer, revenue cycle, and managed services solutions
4/29/2026	Vitrana	Parexel International (EQT, Goldman Sachs)	Vitrana is a developer of an end-to-end pharmacovigilance (PV) technology platform designed to improve the quality, efficiency, and cost of clinical research, development, and patient care
4/15/2026	Conexus Solutions	Axtria (Kedaara Capital)	Conexus Solutions is a provider of outsourced sales, operations, and CRM consulting services for life sciences clients across the Veeva and Salesforce ecosystems
4/3/2026	Coefficient Bio	Anthropic	Coefficient Bio is a biotech AI company offering a platform designed to streamline drug research, manage regulatory strategies, and identify new drug candidates

1. Transaction structured as a continuation vehicle. 2. Represents announcement date; transaction closed 7/1/2026.

Source: Pitchbook, company websites, Business Wire, Public filings.



About Clearsight

Clearsight's Healthcare and Life Sciences Practice focuses on 'Knowledge Economy' businesses serving life sciences companies, providers, and payers. This ecosystem is innovating across professional services, technology, and data to move healthcare forward.

Clearsight Advisors is an investment banking firm dedicated to driving the Knowledge Economy by providing world-class M&A and capital raising solutions exclusively to growth-oriented Business Services and Technology companies. Clearsight combines deep market insights across software, services, and data. Clearsight Advisors, Inc. is a wholly owned subsidiary of Regions Financial Corporation. All securities are offered exclusively through RF M&A Securities LLC, a registered broker-dealer and member of [FINRA](#) and [SIPC](#). For more information about Clearsight, visit www.clearsightadvisors.com.



1650 Tysons Boulevard
Suite 710
McLean, VA 22102

250 Park Avenue
Suite 600
New York, NY 10177



703.672.3100




www.clearsightadvisors.com



[Clearsight Advisors](#)

Select Transactions



This publication has been prepared solely for the use of institutional investors for general information purposes and is not to be construed as: a personalized recommendation; a solicitation or an offer to buy or sell any securities or related financial instruments; legal, tax, financial or accounting advice. Contents are based on information from sources believed to be reliable, but accuracy and completeness cannot be guaranteed. Clearsight has no duty to update the information. Certain sections of this publication may contain forward-looking statements that are based on the reasonable expectations, estimates, projections and assumptions of the authors, but forward-looking statements are not guarantees of future performance and involve risks and uncertainties, which are difficult to predict. The names and marks of other companies or their services or products may be the trademarks of their owners and are used only to identify such companies or their services or products and not to indicate endorsement or sponsorship of Clearsight of its services or products. Clearsight Advisors, Inc. is a wholly owned subsidiary of Regions Financial Corporation. All securities are offered through RF M&A Services LLC, a registered broker-dealer and member of [FINRA](#) and [SIPC](#). For more information about Clearsight visit www.clearsightadvisors.com.